8-K: Harrow Announces Preliminary Q4 and Year-End 2024 Results, Expects Over $280 Million in 2025 Revenue, Audit Delay

Harrow, Inc. reports unaudited preliminary financial results for Q4 and year-end 2024, provides 2025 revenue guidance, and announces a delay in the release of audited financial results due to additional time needed by the new independent auditor.

Summary

• Harrow, Inc. announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2024.
• The company expects revenues between $65 and $67 million for Q4 2024 and between $198 and $200 million for the full year 2024.
• Net income for Q4 2024 is projected to be between $5 and $7 million, while the net loss for the full year 2024 is expected to be between $17 and $19 million.
• Adjusted EBITDA is estimated to be between $21 and $23 million for Q4 2024 and between $39 and $41 million for the full year 2024.
• Harrow is delaying the release of its audited financial results, conference call, and Annual Report on Form 10-K due to the new independent auditor requiring additional time.
• The company provides 2025 revenue guidance of over $280 million, driven primarily by its higher-margin branded business.
• The delay in filing the Form 10-K is not related to any disagreements on accounting principles, financial statement disclosure, or auditing scope or procedure.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there's a delay in the audited results, the preliminary figures and revenue guidance are encouraging. The delay is attributed to the new auditor needing more time, not accounting disagreements, which mitigates concern.

Positives

• Harrow expects to report a net income for Q4 2024.
• The company anticipates revenue growth in 2025, projecting over $280 million.
• Harrow successfully met the annual leverage ratio term under its senior secured loan agreement, avoiding the issuance of warrants to lenders.

Negatives

• Harrow expects to report a net loss for the full year 2024.
• The release of audited financial results is delayed due to the new auditor needing more time.

Risks

• The preliminary financial results are subject to change upon completion of the financial closing procedures and final review by the independent auditors.
• The company faces risks related to its ability to complete the audit of its financial statements.
• There are general risks related to liquidity, operations, competition, economic conditions, and regulatory matters.

Future Outlook

Harrow anticipates revenue growth in 2025, projecting over $280 million, driven by its higher-margin branded business.

Management Comments

• 'We were certainly looking forward to reporting our record financial performance for the fourth quarter and full year and to sharing details on the quarter with our stockholders...'
• 'However, we respect our auditors request for additional time to complete the audit process, as we remain fully committed to comprehensive, accurate, and transparent financial reporting.'
• 'I want to provide 2025 revenue guidance of over $280 million, noting that our higher-margin branded business is expected to drive most of our growth this year.'

Industry Context

Harrow operates in the eyecare pharmaceutical industry, competing with other pharmaceutical companies, outsourcing facilities, and pharmacies. The company focuses on making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without audited figures, but Harrow's revenue guidance of over $280 million for 2025 suggests continued growth in the competitive ophthalmic pharmaceutical market.
• Companies like Novartis (through its Alcon division) and Bausch Health Companies are major players in this space, and Harrow's growth trajectory will be closely watched against their performance.
• Given the focus on branded products, Harrow's margins will be a key differentiator compared to companies primarily focused on generics.

Stakeholder Impact

• Shareholders will be interested in the final audited results and the company's ability to meet its 2025 revenue guidance.
• Employees may be affected by the company's financial performance and growth prospects.
• Customers will be interested in the continued availability and affordability of Harrow's pharmaceutical products.
• Lenders will be interested in the company's ability to service its debt and maintain compliance with loan covenants.

Next Steps

• Harrow intends to schedule a conference call to discuss the results once the audited financial statements are available.
• The company plans to file its Form 10-K and post its Letter to Stockholders and corporate presentation.

Key Dates